AIDS Healthcare Foundation
Pfizer's Selzentry Poised To Be Most Expensive First-Line AIDS Drug
Published in Medical Letter on the CDC and FDA, November 1st, 2009
Responding to today's news that the Food and Drug Administration (FDA) Antiviral Advisory Committee has approved Pfizer Inc.'s AIDS therapy, Selzentry (maraviroc), for use in therapy-naive patients, AIDS Healthcare Foundation (AHF) strongly criticized Pfizer for its current pricing of the drug at an Average Wholesale Price (AWP) of $13,767 per-patient per-year-which, if this price remains when use is expanded, would make it the most expensive first-line AIDS drug on the market.
Selzentry was originally approved by the FDA in August 2007 as a salvage drug-utilized in patients who do not respond favorably, or have developed resistance, to other AIDS drugs-and priced at...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- American Academy of Neurology
New guidelines identify best treatments to help ALS patients live longer, easier - Harvard School of Public Health
Vaccinating boys against human papillomavirus not cost-effective - Louisiana State University Health Sciences Center
LSUHSC's England plays key role in developing new ALS treatment guidelines - Thomas Jefferson University
Researchers identify mechanism that helps bacteria avoid destruction in cells - Wiley-Blackwell
Study identifies significant savings on venous leg ulcer dressings - Alzheimer Disease
EPIX Pharmaceuticals Announces FDA Approval of a Physician-Sponsored IND for Fourth 6-month Open Label Extension of PRX-03140 for Alzheimer's Disease Patient - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
